Biocon Biologics and Civica Join Forces to Revolutionize Insulin Access in the US

Unknown Apr 02, 2026 3 Views

Biocon Biologics Ltd, a subsidiary of Biocon Ltd (BSE: 532523, NSE: BIOCON), has announced a groundbreaking collaboration with Civica, Inc. to expand access to affordable Insulin Aspart in the United States. Under this strategic agreement, Biocon Biologics will supply Insulin Aspart drug substanc...

Stay Ahead – Explore Now! Profit Engine Engaged: Innoviti Hits EBITDA Profitability Three Months Ahead of Plan